本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SHENZHEN, China, March 30, 2025 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "LifeTech", Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries (the "Group") announced the audited consolidated results for the year ended 31 December 2024 (the "Reporting Period"). Revenue increased steadily: The revenue of the Group was approximately RMB1,303.7 million for the year ended 31 December 2024, representing a year-on-year growth of approximately 2.9%. International business made a significant growth: The overseas sales of the Group was approximately RMB346.6 million for the year ended 31 December 2024, representing a year-on-year growth of approximately 26.0%. The two largest overseas markets, namely Asia (excluding China's mainland) and Europe, achieved a sustained rapid growth during the Reporting Period, increasing by approximately 33.6% and 18.6% as compared with the same period of 2023, respectively. Profitability：During the Reporting Period, gross profit was approximately RMB981.4 million, while the gross profit margin was approximately 75.3%. Net profit for the year ended 31 December 2024 was approximately RMB168.5 million, and net profit attributable to owners of the Company for the year ended 31 December 2024, was approximately RMB222.4 million. International Business Achieved Significant Growth, Domestic Market Solidified Foundation for Development The Company steadfastly pursued its mission to meet unmet clinical treatment needs worldwide through a strategic lens focused on innovation and global outreach. During the Reporting Period, the Group has showcased its commitment by rolling out a rich product portfolio of cutting-edge technology and premium academic services, alongside the synergistic amalgamation of its expertise in branding, patents, distribution networks, clinical trials, market registration, and management of global operations. With the effective implementation of the internationalization development strategies, the Group's international business has maintained sustained rapid growth. The revenue generated from overseas market of the Group was approximately RMB346.6 million, representing a significant year-on-year growth of approximately 26.0%, accounted for about 26.6% of the total revenue of the Group. Meanwhile, Asia (excluding China's mainland) and Europe were the two largest overseas market of the Group, continued to maintain a strong growth rate during the Reporting Period, increasing by approximately 33.6% and 18.6% as compared with the same period of 2023, respectively. The sales generated from the Asia market and European market accounted for approximately 11.7% and 10.1% of the total revenue of the Group, respectively. China's mainland remained the foundation and the largest market of the Group. During the Reporting Period, the domestic sales of the Group was approximately RMB957.1 million, which accounted for approximately 73.4% of the total revenue of the Group. The Group's key products, including congenital heart disease (CHD) occluders, left atrial appendage (LAA) occluders, aortic stent grafts and vena cava filters, continued to develop in depth in the China's mainland market during the reporting period, with a wide coverage and a solid market foundation, and continuously maintained its leading position in China market. Core Business Demonstrated Development Resilience Structure Heart Diseases (SHD) Business The products offered by the Group in the SHD business mainly include CHD occluders and LAA occluders. The turnover contributed by the SHD business for the year ended 31 December 2024 was approximately RMB527.6 million, representing a year-on-year growth of approximately 6.4%. The LAA occluder of the Group firmly ranks first in terms of market share among domestic peers in the global market. The revenue generated from the sales of LAA occluders increased by approximately 12.4% as compared with the corresponding period of 2023. Meanwhile, the Group is currently selling three generations of CHD occluders in the global market, aiming to meet various market needs through a differentiated product strategy. During the Reporting Period, the revenue generated from the sales of CHD occluders increased by approximately 2.9% as compared with the same period of 2023. The Group has a diversified product portfolio in the treatment of SHD. Continuous technological innovation and product upgrading will further refine and enrich the product portfolio and sales layout of the Group's SHD business in the global market. Peripheral Vascular Diseases (PVD) Business Products offered by the Group in the PVD business mainly included vena cava filters, thoracic aortic aneurysm stent grafts, abdominal aortic aneurysm stent grafts and iliac artery bifurcation stent grafts. During the Reporting Period, the turnover contributed by the PVD business was approximately RMB751.1 million, representing a year-on-year growth of approximately 6.2%. Among these products, the market shares of vena cava filters and stent grafts occupy a leading position in the domestic market. The revenue generated from the sales of stent grafts and vena cava filters increased by approximately 8.3% and decreased by approximately 3.4% as compared with the same period of 2023, respectively. The Group is striving to provide global patients with technology-leading systemic and comprehensive interventional medical devices solutions to treat PVD. Currently, the Group has taken the lead in building an overall solution for endovascular interventional treatment of the aorta in the global industry. This could bring the Group's PVD business with a strong and long-term competitive edge in the global market. Cardiac Pacing and Electrophysiology (CPE) Business The Group is the first domestic manufacturer in China with a complete product portfolio of domestic implantable cardiac pacemakers with international-level technology and functions. During the Reporting Period, the turnover contributed by the CPE business was approximately RMB25.0 million. Innovation at the Core to Drive the Sustainable Growth Independently developed innovative medical device products could maintain the long-term competitive strengths of the Group to support its solid and sustained development. With a robust lineup of pipeline products, the Group is at the forefront of innovation, boasting products with substantial growth potential and broad market appeal. During the Reporting Period, research and development expenses of the Group were approximately RMB302.9 million (excluding capitalized expenditure) to continuously strengthen its innovation capabilities and accelerate the development and commercialization of its novel products. Smooth progress of product commercialization: Futhrough™Endovascular Needle System, Thrombectomy Aspiration Pump, Balloon Guided Catheter, Distal Access Catheter Kits, Intracranial Aspiration Catheter and HeartTone™ Implantable Cardiac Pacemaker compatible with magnetic resonance imaging ("MRI") obtained the National Medical Products Administration ("NMPA") certification; HeartR™ PDA Occluder, Cera™ PDA Occluder, CeraFlex™ PDA Closure System and Fustar™ Steerable Introducer obtained the CE MDR (Medical Device Regulation) certification. Such products have previously obtained the CE MDD (Medical Device Directive) certification; Aortic Stent Graft System (consists of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System) 【1】, Aortic Arch Stent Graft System (consists of the Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System), Thoracoabdominal Artery Stent Graft System (consists of the G-Branch™ Thoracoabdominal Aortic Stent Graft System, SilverFlow™ PV Peripheral Vascular Stent Graft System and Aortic Extension Stent Graft System), Peripheral Balloon Dilatation Catheter (Large diameter) 【2】, Iliac Bifurcation Device (consists of the G-iliac™ Pro Iliac Bifurcation Stent Graft System and SilverFlow™ Pro Internal Iliac Stent Graft System), Closure Delivery System, SteerEase™-m Introducer, Yoscop™ Multi-loop Snare System and Microcatheter are pending registration approval in China; Note 【1】【2】：Market registration of these two products was approved by NMPA in 2025. Aortic Stent Graft System (consists of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System), Fitaya™ Vena Cava Filter System, Futhrough™ Stent Graft Balloon Catheter, Yuranos™ Abdominal Aortic Stent Graft System, and G-iliac™ Iliac Bifurcation Device are pending registration approval of CE certification; Cera™ PFO Occluder, CS™ Concave Supra-arch Branched Stent-Graft System and X-Clip™ Mitral Valve Clip System are currently at the stage of the pre-registration clinical enrollment in China; IBS Titan™ Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold System is currently at the stage of clinical enrollment in China and in Europe and its CE registration application has been submitted; and IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System has successfully completed the oneyear follow-up and two-year imaging follow-up of the phase II clinical study, and also successfully completed the one-year follow-up of the phase III clinical study, further confirming its safety and efficacy. Additionally, its CE registration application has been submitted. Intellectual Property Rights: Intellectual property is an internal driving force to improve the Group's core competitiveness in the medical device market. As at 31 December 2024, the Group had filed a total of 2,426 valid patent applications, of which 1,089 patents were registered and valid. The Chairman and CEO of LifeTech, Mr. XIE Yuehui Said:In 2024, the Group continued to forge ahead in a complex and volatile market environment. We faced challenges head-on and made joint efforts in research and development, network expansion, production and quality control, and internal control management. We continuously consolidated our leading position in the domestic market and achieved sustained and rapid growth in the international market, demonstrating strong resilience in business development and growth potential. The global medical device industry will embrace tremendous development opportunities driven by both technological innovation and demand upgrading. We will continue to be empowered by innovation, earn a reputation through quality, solidify the foundation for development, and keep delving deeper and making breakthroughs in the global market. We will bring sustainable differential competitive advantages through technological innovation so as to occupy a higher share of the global market and enable more patients to benefit from our innovative products and advanced therapies. Meanwhile, we will also strategically explore new growth opportunities around the globe, integrate and efficiently utilize internal and external advantageous resources, and constantly enhance the overall value of the Group and its global industry influence, so as to create greater value for shareholders and all relevant parties. About LifeTech Scientific Corporation: Established in Shenzhen, China in 1999, LifeTech Scientific Corporation (Stock Code: 1302.HK) is dedicated to the research and development, manufacturing, and marketing of minimally invasive interventional medical devices for the treatment of cardio-cerebrovascular and peripheral vascular diseases. The Company offers innovative treatment solutions for structural heart diseases, peripheral vascular diseases, bradycardia, and neurological diseases. The Company also holds the world's first innovative iron-based bioabsorbable material technology platform. Adhering to the core strategy of innovation and internationalization, the Company maintains a leading market share of its main products in the home country. To date, it has established 7 subsidiaries outside the China mainland. Its business network spans nearly 120 countries and regions worldwide, underscoring its extensive global footprint.
SHENZHEN, China, March 29, 2025 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "LifeTech", Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries (the "Group") announced the audited consolidated results for the year ended 31 December 2024 (the "Reporting Period"). Revenue increased steadily: The revenue of the Group was approximately RMB1,303.7 million for the year ended 31 December 2024, representing a year-on-year growth of approximately 2.9%. International business made a significant growth: The overseas sales of the Group was approximately RMB346.6 million for the year ended 31 December 2024, representing a year-on-year growth of approximately 26.0%. The two largest overseas markets, namely Asia (excluding China's mainland) and Europe, achieved a sustained rapid growth during the Reporting Period, increasing by approximately 33.6% and 18.6% as compared with the same period of 2023, respectively. Profitability：During the Reporting Period, gross profit was approximately RMB981.4 million, while the gross profit margin was approximately 75.3%. Net profit for the year ended 31 December 2024 was approximately RMB168.5 million, and net profit attributable to owners of the Company for the year ended 31 December 2024, was approximately RMB222.4 million. International Business Achieved Significant Growth, Domestic Market Solidified Foundation for Development The Company steadfastly pursued its mission to meet unmet clinical treatment needs worldwide through a strategic lens focused on innovation and global outreach. During the Reporting Period, the Group has showcased its commitment by rolling out a rich product portfolio of cutting-edge technology and premium academic services, alongside the synergistic amalgamation of its expertise in branding, patents, distribution networks, clinical trials, market registration, and management of global operations. With the effective implementation of the internationalization development strategies, the Group's international business has maintained sustained rapid growth. The revenue generated from overseas market of the Group was approximately RMB346.6 million, representing a significant year-on-year growth of approximately 26.0%, accounted for about 26.6% of the total revenue of the Group. Meanwhile, Asia (excluding China's mainland) and Europe were the two largest overseas market of the Group, continued to maintain a strong growth rate during the Reporting Period, increasing by approximately 33.6% and 18.6% as compared with the same period of 2023, respectively. The sales generated from the Asia market and European market accounted for approximately 11.7% and 10.1% of the total revenue of the Group, respectively. China's mainland remained the foundation and the largest market of the Group. During the Reporting Period, the domestic sales of the Group was approximately RMB957.1 million, which accounted for approximately 73.4% of the total revenue of the Group. The Group's key products, including congenital heart disease (CHD) occluders, left atrial appendage (LAA) occluders, aortic stent grafts and vena cava filters, continued to develop in depth in the China's mainland market during the reporting period, with a wide coverage and a solid market foundation, and continuously maintained its leading position in China market. Core Business Demonstrated Development Resilience Structure Heart Diseases (SHD) Business The products offered by the Group in the SHD business mainly include CHD occluders and LAA occluders. The turnover contributed by the SHD business for the year ended 31 December 2024 was approximately RMB527.6 million, representing a year-on-year growth of approximately 6.4%. The LAA occluder of the Group firmly ranks first in terms of market share among domestic peers in the global market. The revenue generated from the sales of LAA occluders increased by approximately 12.4% as compared with the corresponding period of 2023. Meanwhile, the Group is currently selling three generations of CHD occluders in the global market, aiming to meet various market needs through a differentiated product strategy. During the Reporting Period, the revenue generated from the sales of CHD occluders increased by approximately 2.9% as compared with the same period of 2023. The Group has a diversified product portfolio in the treatment of SHD. Continuous technological innovation and product upgrading will further refine and enrich the product portfolio and sales layout of the Group's SHD business in the global market. Peripheral Vascular Diseases (PVD) Business Products offered by the Group in the PVD business mainly included vena cava filters, thoracic aortic aneurysm stent grafts, abdominal aortic aneurysm stent grafts and iliac artery bifurcation stent grafts. During the Reporting Period, the turnover contributed by the PVD business was approximately RMB751.1 million, representing a year-on-year growth of approximately 6.2%. Among these products, the market shares of vena cava filters and stent grafts occupy a leading position in the domestic market. The revenue generated from the sales of stent grafts and vena cava filters increased by approximately 8.3% and decreased by approximately 3.4% as compared with the same period of 2023, respectively. The Group is striving to provide global patients with technology-leading systemic and comprehensive interventional medical devices solutions to treat PVD. Currently, the Group has taken the lead in building an overall solution for endovascular interventional treatment of the aorta in the global industry. This could bring the Group's PVD business with a strong and long-term competitive edge in the global market. Cardiac Pacing and Electrophysiology (CPE) Business The Group is the first domestic manufacturer in China with a complete product portfolio of domestic implantable cardiac pacemakers with international-level technology and functions. During the Reporting Period, the turnover contributed by the CPE business was approximately RMB25.0 million. Innovation at the Core to Drive the Sustainable Growth Independently developed innovative medical device products could maintain the long-term competitive strengths of the Group to support its solid and sustained development. With a robust lineup of pipeline products, the Group is at the forefront of innovation, boasting products with substantial growth potential and broad market appeal. During the Reporting Period, research and development expenses of the Group were approximately RMB302.9 million (excluding capitalized expenditure) to continuously strengthen its innovation capabilities and accelerate the development and commercialization of its novel products. Smooth progress of product commercialization: Futhrough™Endovascular Needle System, Thrombectomy Aspiration Pump, Balloon Guided Catheter, Distal Access Catheter Kits, Intracranial Aspiration Catheter and HeartTone™ Implantable Cardiac Pacemaker compatible with magnetic resonance imaging ("MRI") obtained the National Medical Products Administration ("NMPA") certification; HeartR™ PDA Occluder, Cera™ PDA Occluder, CeraFlex™ PDA Closure System and Fustar™ Steerable Introducer obtained the CE MDR (Medical Device Regulation) certification. Such products have previously obtained the CE MDD (Medical Device Directive) certification; Aortic Stent Graft System (consists of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System) 【1】, Aortic Arch Stent Graft System (consists of the Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System), Thoracoabdominal Artery Stent Graft System (consists of the G-Branch™ Thoracoabdominal Aortic Stent Graft System, SilverFlow™ PV Peripheral Vascular Stent Graft System and Aortic Extension Stent Graft System), Peripheral Balloon Dilatation Catheter (Large diameter) 【2】, Iliac Bifurcation Device (consists of the G-iliac™ Pro Iliac Bifurcation Stent Graft System and SilverFlow™ Pro Internal Iliac Stent Graft System), Closure Delivery System, SteerEase™-m Introducer, Yoscop™ Multi-loop Snare System and Microcatheter are pending registration approval in China; Note 【1】【2】：Market registration of these two products was approved by NMPA in 2025. Aortic Stent Graft System (consists of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System), Fitaya™ Vena Cava Filter System, Futhrough™ Stent Graft Balloon Catheter, Yuranos™ Abdominal Aortic Stent Graft System, and G-iliac™ Iliac Bifurcation Device are pending registration approval of CE certification; Cera™ PFO Occluder, CS™ Concave Supra-arch Branched Stent-Graft System and X-Clip™ Mitral Valve Clip System are currently at the stage of the pre-registration clinical enrollment in China; IBS Titan™ Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold System is currently at the stage of clinical enrollment in China and in Europe and its CE registration application has been submitted; and IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System has successfully completed the oneyear follow-up and two-year imaging follow-up of the phase II clinical study, and also successfully completed the one-year follow-up of the phase III clinical study, further confirming its safety and efficacy. Additionally, its CE registration application has been submitted. Intellectual Property Rights: Intellectual property is an internal driving force to improve the Group's core competitiveness in the medical device market. As at 31 December 2024, the Group had filed a total of 2,426 valid patent applications, of which 1,089 patents were registered and valid. The Chairman and CEO of LifeTech, Mr. XIE Yuehui Said:In 2024, the Group continued to forge ahead in a complex and volatile market environment. We faced challenges head-on and made joint efforts in research and development, network expansion, production and quality control, and internal control management. We continuously consolidated our leading position in the domestic market and achieved sustained and rapid growth in the international market, demonstrating strong resilience in business development and growth potential. The global medical device industry will embrace tremendous development opportunities driven by both technological innovation and demand upgrading. We will continue to be empowered by innovation, earn a reputation through quality, solidify the foundation for development, and keep delving deeper and making breakthroughs in the global market. We will bring sustainable differential competitive advantages through technological innovation so as to occupy a higher share of the global market and enable more patients to benefit from our innovative products and advanced therapies. Meanwhile, we will also strategically explore new growth opportunities around the globe, integrate and efficiently utilize internal and external advantageous resources, and constantly enhance the overall value of the Group and its global industry influence, so as to create greater value for shareholders and all relevant parties. About LifeTech Scientific Corporation: Established in Shenzhen, China in 1999, LifeTech Scientific Corporation (Stock Code: 1302.HK) is dedicated to the research and development, manufacturing, and marketing of minimally invasive interventional medical devices for the treatment of cardio-cerebrovascular and peripheral vascular diseases. The Company offers innovative treatment solutions for structural heart diseases, peripheral vascular diseases, bradycardia, and neurological diseases. The Company also holds the world's first innovative iron-based bioabsorbable material technology platform. Adhering to the core strategy of innovation and internationalization, the Company maintains a leading market share of its main products in the home country. To date, it has established 7 subsidiaries outside the China mainland. Its business network spans nearly 120 countries and regions worldwide, underscoring its extensive global footprint.
霸氣縱橫、輕盈玲瓏、持久耐用Big Bang Unico 的設計靈感，源自奧運金牌得主、24 次大滿貫冠軍得主 Novak Djokovic 的贏家心態 要隨時掌握最新資訊，請關注 @Hublot #Hublot 巴黎2024年11月20日 /美通社/ -- Hublot 宇舶表受 Djokovic 令人難以置信的創紀錄成就所啟發，設計了一款腕錶，能夠捕捉 Novak Djokovic 大使 Novak Djokovic 在球場上的敏捷性，同時彰顯出 Hublot 對可持續創新的態度。兩者攜手推出一款非凡的腕錶，靈感源自 Novak Djokovic 成為有史以來最偉大的網球運動員的力量和決心。由 Hublot 宇舶表對創新和獨特材料精通的承諾驅動，Big Bang Unico Novak Djokovic 由 Djokovic 的 HEAD 球拍和 Lacoste 馬球衫製成。Djokovic 的球拍和馬球衫獲得第二次生命，被改造成一款出色腕錶，成為獨特的護身符。 Hublot Big Bang Unico Novak Djokovic 記者和特別嘉賓聚集在巴黎，體驗奧運金牌得主和 24 座大滿貫冠軍身歷其境體驗：透過獨特的表演、Hublot 宇舶表行政總裁 Julien Tornare 和 Novak Djokovic 的討論，以及 Big Bang Unico Novak Djokovic 腕錶的官方揭曉。Djokovic 是一位無與倫比的球員，今年較早時，他在光明之城贏得了職業生涯中另一個非凡的冠軍，贏得了奧運金牌；Djokovic 以這輝煌勝利創造了歷史，他是史上第五位完成金滿貫的球員，橫掃所有四個大賽冠軍和一枚奧運單打金牌。 傳奇心態 Novak Djokovic 於 2021 年成為 Hublot 宇舶表家族一員。從那時起，這間瑞士豪華製錶商一直支持網球運動員的最偉大成就，見證 Djokovic 再次證明自己是網球的王者。 Djokovic 的故事，現已是網球界的不朽傳奇。Djokovic 於 2003 年成為專業網球人士，一直在改寫網球歷史、打破紀錄、挑戰賠率，克服逆境，化不可能為可能。自從 2008 年在澳洲公開賽贏得他的第一個大滿貫賽事後，Djokovic 就主宰了網球史上競爭最激烈的時期，球技日益精湛。勇奪第 24 座大滿貫冠軍的 Djokovic，在他的旅程中閃耀著熱情、意志和決心，並鞏固了他持續的遺產。 Djokovic 致力於成為最好的人，並全力追求自己的夢想，體現了 Hublot 宇舶表在高級製錶領域中同樣強大的獨特理念。挑戰越大，克服挑戰的榮耀就越大。 「要達到我今時今日的位置，這需要大量的身體工作，最重要的是精神上的工作。遊戲的心理學非常重要，當我在玩樂時，每分每秒都要精準和用心。這對我在準備和比賽時的穿著尤其重要，因為穿著成為我身體、我心靈的一部分。每一項細節，對我保持專注和決心的能力至關重要。這款新腕錶是這種思維的延伸，並代表了我在 2023 賽季的關鍵時刻，這是我職業生涯中具有里程碑意義的一年。這腕錶是每一場比賽，每一刻的象徵。與 Hublot 宇舶表合作製作這款特殊腕錶，真是令人難以置信的體驗。」 Novak DjokovicHublot 形象大使和網球 GOAT (Greatest of all time) 融合卓越與創新 Hublot 宇舶表接受了一項挑戰：創造出具有可持續性組件，而且非常輕巧的手錶。Hublot 宇舶表以突破研發界限而聞名，不僅能創造一種新的物料，更能創造出高度個人化的物料。Hublot 宇舶表開發出一款由 25 個 HEAD 球拍以及 17 條深藍色和 15 條淺藍色 Lacoste 短褲製成的複合物料，這些衣物由 Djokovic 在 2023 賽季期間使用，而這一年是世界見證 Djokovic 創歷史並以 24 座大滿貫單打冠軍打破紀錄的一年。 這些物料的開發與使用，讓腕錶儘可能輕盈，同時不失任何強度或彈性。在許多方面，這款腕錶的研發過程反映了 Djokovic 致力於卓越的目標的決心。 構成手錶錶殼和錶圈的複合物料，由環氧樹脂與石英粉和玻璃纖維強化而成，並與回收的球拍和衣物融為一體。產生的物料，點綴了淺藍色、深藍色的紡織物和黑色碳纖維，營造出獨特的迷彩美學。一種創新的方法，代表 Hublot 宇舶表對無限重新發明的凌雲壯志。 為確保手腕感覺輕盈，Hublot 宇舶表必須找出能夠減輕腕錶重量的方法。這間瑞士奢華製錶商棄用傳統的藍寶石水晶，而選擇了鋼化大猩猩玻璃，這是一種用於高端電子產品的材料，比藍寶石輕兩倍。Hublot 宇舶表的創新和材料團隊不懈努力創造獨特的腕錶，同時追求品牌的參與，邁向有意義的產品，以環保意識製造。 這款腕錶的核心是 Unico 製造計時機芯。此機芯是品牌大膽、與眾不同特質的代名詞，是這款特別作品的必然之選。儘管如此，為減輕腕錶的重量，標準的黃銅 Unico 機芯必須重新設計。為此，Hublot 宇舶表選擇了鋁質，因其輕盈而備受讚譽，並以淺藍色或灰色陽極氧化，以反映錶殼的迷彩色方案。如此一來，Hublot 宇舶表的工程師能夠將機芯的重量減少 27%，即減少了近三分之一的重量。鋁也用於一些錶殼組件，如側片 (3H-9H)、副錶圈、錶圈耳、按鈕、錶冠和錶背。 Big Bang Unico Novak Djokovic 配有四條錶帶，適用於四種不同款式。第一款錶帶是「Lacoste」網球腕帶，採用 One Click 系統固定在手錶頭上，使手錶成為完美的網球伴侶。第二款是藍色鬆緊帶，這種組合總重 49.5 克，比網球更輕！第三款採用淺藍色魔術貼錶帶，搭配拋光藍色鋁合金運動扣。最後一款式是白色橡膠錶帶，搭配鈦金屬開合扣。 極具收藏價值 網球運動員和收藏家的粉絲都會喜歡腕錶新增的細節，例如黃色的第二推桿或略圓頂和彎曲的錶圈螺絲，讓人想起網球。Novak Djokovic 標誌可見於錶鏡和擺陀上。 Big Bang Unico Novak Djokovic 腕錶，限量 100 件，裝載於 Hublot 宇舶表可持續採購的優質木質錶盒內。此錶盒包括鉸鏈部分，完全由橡木製成，由大部分大型可追溯的木材雕刻，其採購和製造都會促進短供應鏈。錶盒採用獨特設計，專為此限量版打造。 腕錶的擁有者，還將獲得一條 Lacoste 運動腕帶和由 Hublot 宇舶表形象大使、24 座大滿貫單打冠軍記錄保持者 Novak Djokovic 親筆簽名的 Lacoste 馬球。 成為第一位擁有 Hublot 宇舶表 Big Bang Unico Novak Djokovic 人之一。現可 Hublot.com 和我們的精品店網上購買。 HUBLOT 宇舶表 Hublot 宇舶表是一間瑞士腕錶製造商，成立於1980年，總部位於尼翁 (Nyon)。這間公司顛覆傳統，首次在腕錶中將黃金與橡膠表帶巧妙融合，錶殼的設計靈感更是源自船舶的舷窗（法語中的hublot）。融合的藝術（The Art of Fusion）就此誕生，將傳統、創新、工藝、世界和天賦融為一體。Hublot宇舶表成為品牌的美學和技術標誌。 Hublot宇舶表的品牌形象在2005年憑著 Big Bang 系列得以強化，展現出品牌在複雜功能、自研機芯以及採用尖端材質方面的無與倫比的專業知識。在這一款腕錶上，碳纖維、鈦金屬、陶瓷和藍寶石水晶玻璃等物料的使用均達到了技術上的極限。 憑藉「敢為人先、獨一無二、與別不同」（Be First, Unique and Different）的品牌哲學，Hublot 宇舶表開創了顛覆傳統的卓越製錶之道，這種製錶理念逐漸延伸至其他擁有創新設計的腕錶系列：Classic Fusion、Shaped Collection (Spirit of Big Bang、Square Bang) 和 Manufacture Pieces。這些腕錶系列均展現出 Hublot 令人驚嘆的工藝水準，既採用了 Hublot 鍾愛的材質（例如 Magic Gold、鮮艷亮麗的陶瓷和藍寶石水晶玻璃），同時也搭載了 Hublot 自研的機芯（包括 Unico 計時碼表機芯、Meca-10 機芯以及 Tourbillon、Cathedral Minute Repeater 及特製 Manufacture Pieces 等高級複雜功能）。 Hublot 宇舶表的全球足跡還延伸至與知名合作夥伴建立合作關係，包括足球領域。Hublot Loves Football 已成為世界上最大的體育賽事（如 FIFA 世界盃™、英超、歐冠聯賽、歐洲歐洲歐洲™）和通過其大使中的口號。這種對足球的熱愛亦延伸至藝術、設計、音樂、運動、高級餐飲和航海等領域。最後，Hublot 宇舶表積極參與與 SORAI 和 Polar Pod 攜手推動的聯合環保專案，彰顯其對當今重要議題的關注。 超過 140 間專賣店遍佈全球各地，與 Hublot.com 電子商務網站一起，秉承 Hublot 宇舶表的熱情和價值觀。 Big Bang Unico Novak Djokovic 參考編號 錶殼 底蓋 錶圈 441.QKB.5120.NR.DJO24 限量發行 100 枚 重量 魔術貼錶帶上: 54g 鬆緊帶上: 49.5g 橡膠錶帶上：75g 網球腕帶上：65g 啞光藍色再生複合物料，加上 Novak Djokovic 的短褲和球拍 直徑：42 mm 厚度：14.5 mm 防水深度：10 ATM / 100 M 拋光天藍陽極氧化鋁 啞光藍色再生複合物料，加上 Novak Djokovic 的短褲和球拍 錶盤 機芯 錶帶與錶扣 價格 啞光天藍與白色發光指標 獨立製造，自動上鏈 天藍 PVD 鋁金屬計時碼錶 頻率：4 Hz (28'800 A/H) 動力儲備（小時）：72 組件數量：354 珠寶：43 第一條錶帶：網球腕帶 第二條錶帶：藍色彈性 第三條錶帶：藍色魔術貼緊固件布 第四條錶帶：白色橡膠錶帶 拋光藍色鋁合金運動扣（用於魔術貼手帶） 鈦金屬開合扣（用於橡膠錶帶） 瑞士法郎 48,000 54'900 歐元 52 萬美元 45'300 英鎊 Hublot Big Bang Unico Novak Djokovic Hublot Big Bang Unico Novak Djokovic Hublot ambassador Novak Djokovic wearing Big Bang Unico Novak Djokovic Hublot ambassador Novak Djokovic wearing Big Bang Unico Novak Djokovic Hublot ambassador Novak Djokovic wearing Big Bang Unico Novak Djokovic
ROBUST, LIGHT, SUSTAINABLE: A BIG BANG UNICO INSPIRED BY OLYMPIC GOLD MEDALIST AND 24 GRAND SLAM TITLE HOLDER NOVAK DJOKOVIC'S WINNING MINDSET To stay up to date, follow: @Hublot #Hublot PARIS, Nov. 20, 2024 /PRNewswire/ -- Inspired by Djokovic's incredible record-breaking achievements, Hublot designed a watch that captures Hublot Ambassador Novak Djokovic's agility on the court and highlights Hublot's approach to sustainable innovation. Together, they present an extraordinary watch inspired by the strength and determination that led Djokovic to become the greatest tennis player of all time. Driven by Hublot's commitment to innovation and unique mastery of materials, the Big Bang Unico Novak Djokovic is made of Djokovic's HEAD racquets and Lacoste polos. Novak Djokovic's racquets and shirts are metamorphosed into an exceptional watch that takes on a second life as a unique talisman. Hublot Big Bang Unico Novak Djokovic Journalists and special guests gathered in Paris for an immersive experience into Olympic gold medalist and 24 Grand slam titles holder Djokovic's winning mindset, brought to life through a unique performance, a discussion between Hublot CEO, Julien Tornare and Novak Djokovic, and the official reveal of the Big Bang Unico Novak Djokovic. The tone was set by the charisma of Djokovic, an unmatched player, who earlier this year in the City of Light aced another remarkable career title winning Olympic gold; with this brilliant triumph Djokovic made history as only the 5th player to complete the Golden Slam, winning all four major titles and an Olympic gold medal in singles. A Legendary Mindset Novak Djokovic became a part of the Hublot family in 2021. Since then, the Swiss luxury watchmaker has been there to support the tennis player's greatest achievements and watch Djokovic reaffirm himself as the tennis GOAT. Djokovic's story is now legendary. Djokovic turned professional in 2003 and has rewritten tennis history, breaking records, defying the odds, achieving the impossible and overcoming adversity. Since winning his first Grand Slam at the Australian Open in 2008, Djokovic has dominated the most competitive period in tennis history, elevating the game at every turn. Now a 24-time Grand Slam singles champion, Djokovic's passionate will and determination have shone through in his journey and solidified his ongoing legacy. By striving to be the best and giving his all-in pursuit of his dreams, Djokovic embodies the same powerful values that define Hublot's unique approach to fine watchmaking. The bigger the challenge, the more glory in overcoming it. "To reach where I am today, it has required extensive work both physically and most importantly, mentally. The psychology of the game is very important, and when I play, each moment needs to be precise and intentional. This is especially true with what I wear during preparation and competition, as it becomes part of my body, my mind. Every detail is critical to my ability to stay focused and determined. This new watch is an extension of this mindset and represents key moments from my 2023 season, a landmark year in my career. It is a symbol of every game, every moment. It has been an incredible experience to collaborate with Hublot to create this special watch." NOVAK DJOKOVICHUBLOT AMBASSADOR AND TENNIS GOAT A Fusion of Excellence and Innovation Hublot was given a challenge: to create an incredibly light watch with a sustainable component. Known for pushing the boundaries in terms of research and development, Hublot was able to not only create a new material but a highly personal one at that. Hublot developed a composite made up of 25 HEAD rackets as well as 17 dark blue and 15 light blue Lacoste polos used by Djokovic during his 2023 season, the year in which the world witnessed Djokovic make history and break records with 24 Grand Slams singles titles. These materials have been developed and used to make the watch as light as possible without losing any strength or resilience. In many ways, the R&D process for this watch mirrors Djokovic's determination to aim for excellence. The composite that makes up the case and bezel of the watch is made of Epoxy resin reinforced with quartz powder and glass veil that has been fused with the recycled rackets and shirts. The resulting material is speckled with fragments of light & dark blue textiles and black carbon to create a singular camo aesthetic. An innovative approach, representative of Hublot's ambition for endless reinvention. To ensure a feather-light feeling on the wrist, Hublot had to find a way to reduce the weight of the watch. Instead of using traditional sapphire crystal, the Swiss luxury watchmaker has chosen tempered Gorilla glass, a material used in high-end electronics and two times lighter than sapphire. An achievement made possible by the relentless drive of Hublot's innovation and materials teams to create singular watches while pursuing the brand's engagement to move towards meaningful products, made with awareness. At the heart of the watch lies the Unico manufacture chronograph movement. Synonymous with the bold and always different character of the brand, the movement was a natural choice for this special piece. Nonetheless, the standard Unico movement in brass had to be reinvented to reduce the weight of the watch. To do so, Hublot chose aluminum, prized for its lightness, and anodized in light blue or gray to echo the camo color scheme of the case. In doing so, Hublot's engineers were able to reduce the weight of the movement by 27%, shedding almost a third of its weight. Aluminum has also been used for some case components such as side pieces (3H-9H), sub-bezel, bezel lugs, pushers, crown and case-back. The Big Bang Unico Novak Djokovic comes with four straps for four different styles. The first bracelet is a "Lacoste" tennis wristband that attaches to the watch head with the One Click System, making the watch the perfect tennis companion. The second style is a blue elastic strap, this combination weighs a total of 49.5 grams, lighter than a tennis ball! The third style features a light blue Velcro strap with a polished blue aluminum sports buckle. The last style is a white rubber strap with titanium deployant buckle. Highly Collectible Fans of the tennis player and collectors alike will appreciate the details that have been added to the watch, such as a yellow second pusher or the slightly domed and curved bezel screws reminiscent of a tennis ball. The Novak Djokovic logo is visible on the glass and on the oscillating weight. The Big Bang Unico Novak Djokovic, limited to 100 pieces, is housed in Hublot's sustainably sourced, high quality wooden watch box. Created entirely from oak, including its hinges, it is carved from mostly massive, traceable wood, whose sourcing and manufacture both promote short supply chains. The watch box features a unique design created exclusively for this limited-edition. Owners of the watch will also receive a Lacoste sport wristband and a Lacoste polo signed by Hublot Ambassador and all-time record-holder of 24 Grand Slam single titles, Novak Djokovic. Be among the first to own the new Hublot Big Bang Unico Novak Djokovic. Available now online at Hublot.com and in our Boutiques. HUBLOT Hublot is a Swiss watch manufacturer founded in 1980 and based in Nyon. For its first ever timepiece, this fundamentally disruptive company combined gold with a rubber strap in a case with a design inspired by a ship's porthole (hublot in French). Thus, the Art of Fusion was born, blending tradition, innovation, craftsmanship, worlds and talents. It became the brand's aesthetic and technical signature. This identity was strengthened in 2005 with the Big Bang, which attested to an unrivalled know-how in terms of complications, manufacture movements and state-of-the-art materials. Carbon, titanium, ceramic and sapphire have been developed on this model to technical extremes. This ground-breaking, high-quality approach to watchmaking is summed up in its philosophy 'Be First, Unique and Different.' It gradually led to other collections with innovative designs: Classic Fusion, Shaped Collection (Spirit of Big Bang, Square Bang) and Manufacture Pieces. These draw on high levels of craftsmanship, both in terms of the materials so dear to Hublot (such as Magic Gold, brightly-coloured ceramics and sapphires) and its manufacture movements (Unico chronograph, Meca-10 and high complications such as the Tourbillon, the Cathedral Minute Repeater and the specific Manufacture Pieces movements). Hublot's world extends to powerful partnerships including football. 'Hublot Loves Football' has become the slogan at the world's biggest sporting events (such as the FIFA World Cup™, Premier League, UEFA Champions League, UEFA EURO™) and through its ambassadors. This love of football continues in art, design, music, sport, fine dining and sailing. Lastly, Hublot's implication in joint environmental projects with SORAI and Polar Pod reflects its concern for the issues of the day. Over 140 boutiques around the world share Hublot's fervour and values, alongside the Hublot.com e-commerce site. BIG BANG UNICO NOVAK DJOKOVIC REFERENCE CASE CASEBACK BEZEL 441.QKB.5120.NR.DJO24 Limited to 100 pieces WEIGHT On Velcro Strap: 54g On Elastic Strap: 49.5g On Rubber strap: 75g On Tennis Wristband: 65g Matte blue recycled composite with Novak Djokovic's polos and racket Diameter: 42 mm Thickness: 14.5 mm Water resistance: 10 ATM / 100 M Polished Sky Blue Anodizing Aluminium Matte blue recycled composite with Novak Djokovic's polos and racket DIAL MOVEMENT STRAP AND CLASP PRICE Matte sky blue with white luminescent indexes Unico Manufacture, Self-Winding Chronograph in Sky Blue PVD Aluminium Frequency: 4 Hz (28'800 A/H) Power reserve (hours): 72 Number of components : 354 Jewels : 43 first strap: tennis wristband second strap: blue elastic third strap: blue velcro fastener fabric fourth strap: white rubber strap Polished Blue Aluminium Sport buckle (for velcro bracelet) Titanium Deployant Buckle (for rubber strap) CHF 48'000 EUR 54'900 USD 52'700 GBP 45'300 Hublot Big Bang Unico Novak Djokovic Hublot Big Bang Unico Novak Djokovic Hublot ambassador Novak Djokovic wearing Big Bang Unico Novak Djokovic Hublot ambassador Novak Djokovic wearing Big Bang Unico Novak Djokovic Hublot ambassador Novak Djokovic wearing Big Bang Unico Novak Djokovic
當中有一項專為小零件加工及醫療應用而設的新產品 匹茲堡2024年10月26日 /美通社/ -- Kennametal Inc.（紐約證券交所：KMT）正在推出新刀片和切削刀具，擴大其車削產品組合 ，這些刀具大幅擴展其在小型零件和醫療加工領域的加工能力。三種新產品──TopSwiss™ 車削刀片和微型鑽孔固體 (MBS) 刀具，以及 KCU25B 車削刀片──是專為提高產量、提升零件品質、減少錯誤，以及協助客戶達到精準、乾淨的結果而設計。 TopSwiss™ 車削刀片 全球產品管理副總裁 Scott Etling 表示：「在我們傳統高性能車削產品組合的基礎上加入這些產品，也表現出我們為全球所有客戶提供一站式服務的決心。」KCU25B 和新的 TopSwiss 產品是我們持續創新的證明，也反映出我們車削解決方案產品線系列的演變。」 Kennametal 的全新 TopSwiss™ 車削刀片專為瑞士型小零件加工而設計，適合低進給、高切削深度的醫療、航太與國防、一般工程與運輸應用。此車削產品組合的特點： - 提供四種新的硬質合金等級、一種新的陶瓷等級和七種新的幾何形狀。- 直邊和彎邊切削刃可在低進給、高 DOC 應用中，提供穩定的切削加工，使切屑流出排除順暢。- 拋光精加工幾何形狀，可增加耐焊接性並改善表面精加工。- 中等和精加工刮邊幾何形狀，有助提高進給率，實現卓越的表面品質。- 多種幾何形狀具有高斷屑壁和大凹槽，排屑性能更好。 全新微型鑽孔固體 (MBS) 刀具可在較小的應用中加工，功能更多，靈活性更高，並承諾提供鋒利的切削刃、低切削力和優異的排屑性能，從而延長刀具壽命，讓表面光潔度更出色。TopSwiss 產品系列中的最新產品，包括高性能的內徑車削，內徑可小至 Ø0.3mm (0.012")，精密研磨的刀片桿在設計上提供了更高精度與穩定性；超過 1,100 種標準項目，可為各種應用提供合適的刀把與刀片。 Etling 表示：「我們很自豪地為 TopSwiss 平台提供更細小的刀具解決方案，可滿足最微小加工專案的需求，同時保證一致性與可靠性，以支援熄燈作業。」 KCU25B 車削刀具也是全新產品，提供強大的粗加工和中加工金屬切削解決方案，適用於加工鋼、不銹鋼、鑄鐵和高溫合金的航太與國防、能源、一般工程和運輸車間。KCU25B 刀片也採用 Kennametal 專有 Kennametal 專有的 KenGold PVD 塗層，提供多層保護，以提高側翼和抗崩角能力。 Kennametal 簡介Kennametal Inc. 擁有超過 85 年的工業技術領導地位，透過材料科學、工具和耐磨解決方案，為客戶提供生產力。Kennametal 協助其遍及航太與國防、土木工程、能源、一般工程與運輸等領域的客戶，精準而有效率地製造產品。每天約有 8,400 名員工，協助近 100 個國家的客戶保持競爭力。Kennametal 在 2024 財政年度的營收為 20 億美元。了解更多資訊，請瀏覽 www.kennametal.com 。請在以下平台追蹤 @Kennametal：Instagram、Facebook、LinkedIn 以及 YouTube。 微型鑽孔固體 (MBS) KCU25B 車削刀片
One New Offering Specific to Small Parts Machining & Medical Applications PITTSBURGH, Oct. 25, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) is expanding its turning portfolio with the introduction of new inserts and cutting tools that significantly broadens its machining capabilities in the small parts and medical machining space. The three new products –TopSwiss™ Turning Inserts and Micro Boring Solid (MBS) tooling, and KCU25B Turning Inserts – are designed to improve output, enhance component quality, reduce errors and help customers achieve accurate and clean results. TopSwiss™ Turning Inserts "The addition of these products builds on our legacy portfolio of high-performance turning products, as well as our ambition to become a one-stop shop for all customers globally," said Scott Etling, Vice President of Global Product Management. "KCU25B and the new TopSwiss offering are a testament to our continuous innovation and speaks to the evolution of our turning solutions product lineup." Kennametal's new TopSwiss™ Turning Inserts are uniquely designed for Swiss-type small parts machining and engineered for low feed, high depth-of-cut applications in medical, as well as aerospace and defense, general engineering and transportation. The portfolio features: - Four new carbide grades, one new cermet grade and seven new geometries.- Straight and curved cutting edges for stable cuts and smooth chip flow in low feed, high DOC applications.- Polished finishing geometries for increased welding resistance and improved surface finishing.- Medium and finishing wiper geometries for increased feed rates and superior surface quality.- Several geometries with high chip breaker walls and large pockets for better chip evacuation. New Micro Boring Solid (MBS) tooling allows for the machining of even smaller applications with greater versatility and flexibility, and promises sharp cutting edges, low cutting forces and superior chip evacuation that result in longer tool life and excellent surface finishes. The latest in the TopSwiss lineup includes high performance internal turning in bores as small as Ø0.3mm (0.012"), precision ground insert shanks for high accuracy and stability, and over 1,100 standard items provide the right holder and insert for each application. "We are proud to complement the TopSwiss platform with even smaller tooling solutions to meet the needs of the most minute machining projects while also guaranteeing consistency and reliability to support lights out operations," says Etling. Also new, KCU25B Turning Inserts offer a powerful roughing and medium machining metal cutting solution for aerospace and defense, energy, general engineering and transportation shops working with steels, stainless steels, cast iron and high-temp alloys. Ideal for the most common turning, grooving and cut-off applications, KCU25B inserts also feature Kennametal's proprietary KENGold PVD coating—delivering multiple layers of protection for better flank and chipping resistance. About KennametalWith over 85 years as an industrial technology leader, Kennametal Inc. delivers productivity to customers through materials science, tooling and wear-resistant solutions. Customers across aerospace and defense, earthworks, energy, general engineering and transportation turn to Kennametal to help them manufacture with precision and efficiency. Every day approximately 8,400 employees are helping customers in nearly 100 countries stay competitive. Kennametal generated $2 billion in revenues in fiscal 2024. Learn more at www.kennametal.com. Follow @Kennametal: Instagram, Facebook, LinkedIn and YouTube. Micro Boring Solid (MBS) KCU25B Turning Inserts
A12 藝術空間
PVD
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
